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Respiratory tract infections remain a common and significant 
source of morbidity and mortality in children worldwide. 
This is of relevance in low- to middle-income countries where 
pneumonia is an important cause of death in children under 
5 years of age.[1] With global access to effective immunisation 
programmes having resulted in a decline in the incidence of 
bacterial-associated pneumonia, respiratory viruses have emerged 
as important aetiological agents in childhood pneumonia. This 
holds true in high-income countries, where respiratory viruses 
are the commonest cause of childhood pneumonia.[1,2] Respiratory 
syncytial virus (RSV) is the leading viral cause of pneumonia in 
high- and low-income countries.[2-4]
The prevalence of adenovirus by polymerase chain reaction (PCR) 
testing of nasopharyngeal aspirates in childhood pneumonia cases in 
South Africa (SA) has been reported to be 19 - 26%.[5,6] However, the 
pathogenic role of adenovirus in childhood pneumonia is unclear. Some 
studies report an increased prevalence of adenovirus in pneumonia 
cases, while others found a similar prevalence in population-matched 
controls.[6,7] The ability of some adenovirus strains to cause severe 
and fatal necrotising pneumonia has been described.[8.9] Furthermore, 
long-term sequelae following adenovirus-associated pneumonia 
(AVP), including bronchiectasis, bronchiolitis obliterans, unilateral 
hyperlucent lung and persistent abnormal pulmonary function, have 
been reported.[8,10-13]
The clinical presentation, complications and outcome of AVP in 
SA children are unknown. Furthermore, the role of HIV infection 
and malnutrition in the outcome of AVP is unknown.
Objective
To document the presentation, clinical course and outcome of AVP at 
a tertiary paediatric referral hospital in SA.
Methods
Study design and patient selection
A retrospective descriptive study was conducted in children 0 - 
13 years of age admitted with laboratory-confirmed AVP to Red 
Cross War Memorial Children’s Hospital (RCWMCH), a tertiary 
paediatric hospital in Cape Town, SA. Children admitted from 1 Jan-
uary to 31  December 2011 were included. For the purposes of the 
study, AVP was defined as clinician-diagnosed pneumonia or lower 
respiratory tract infection (LRTI; cough, tachypnoea with or without 
chest indrawing) and positive adenovirus PCR from any respiratory 
tract samples, which included tracheal aspirates, bronchoalveolar 
lavage, induced sputum and nose swabs or nasopharyngeal aspirates. 
Adenovirus subtypes were not identified in routine clinical samples. 
Children without pneumonia or LRTI documented in the records or 
laboratory request form details were excluded. The National Health 
Laboratory Service (NHLS) database was searched to extract all 
PCR adenovirus-positive respiratory samples with the diagnosis of 
pneumonia, bronchiolitis or LRTI collected in children admitted 
to RCWMCH during the study period. Respiratory viruses were 
identified using SeeplexRV7 Detection assay (Seegene, Korea), 
which includes influenza A and B, human metapneumovirus, RSV, 
rhinovirus A, parainfluenza virus and adenovirus.
Clinical and laboratory data
The medical records of identified patients were retrieved and relevant 
data were recorded on a data capture form. Clinical and demographic 
information at the time of hospital admission for community-acquired 
AVP cases, or acquisition of adenovirus infection in hospital-acquired 
AVP cases, was collected. The presence of fever (temperature >38oC 
for >48 hours), diarrhoea, conjunctivitis and skin rash was recorded. 
AVP cases were classified into community acquired or hospital 
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acquired. Community-acquired AVP was defined as AVP confirmed 
within 48 hours of hospital admission. Hospital-acquired AVP was 
defined as AVP acquired >48 hours after hospital admission when the 
presenting illness on admission was not pneumonia.
The HIV status of patients was classified as HIV-exposed but 
uninfected, HIV-infected or HIV-unexposed. In the HIV-infected 
group, CD4 count and percentage, HIV viral load and antiretroviral 
treatment details were recorded. The nutritional status of each child 
was determined by calculating the World Health Organization 
(WHO) weight-for-age z-score (WAZ score) using igrowup macro for 
Stata (WHO Anthro version 3.2.2; StataCorp, USA). Malnutrition was 
defined as a WAZ score of <–2. The presence of an underlying medical 
condition was recorded and categorised as cardiac, respiratory, renal, 
neurological, immune suppression, prematurity or other.
Routine laboratory investigations recorded were total white cell 
count (WCC), haemoglobin, C-reactive protein (CRP) and pro-
calcitonin (PCT) at the time of hospital admission. The presence of 
significant laboratory-confirmed co-infections was documented and 
recorded as other respiratory viruses, positive blood culture, and 
tuberculosis (TB) (positive culture of Mycobacterium tuberculosis 
from any site).
Pneumonia severity was established according to the presence 
or absence of hypoxia at presentation (oxygen saturation <90% in 
room air), need for intensive care unit (ICU) admission and need 
for ventilator support. The ventilation modality and total duration of 
ventilation and ICU stay were recorded.
Outcome measures
Two outcome measures were examined: development of persistent 
lung disease (PLD) and in-hospital mortality. PLD was defined as 
the persistence of clinical signs of respiratory disease as documented 
in the medical records and/or need for supplemental oxygen beyond 
30 days of hospital admission.
Data analysis
Data were collected and entered into EpiData Entry version 2.0 
(Denmark). Thereafter statistical analysis was done using SPSS 
version 22.0 (IBM, USA). Data were tested for normality using 
the Shapiro-Wilks W-test. Continuous variables were expressed 
as means with standard deviations (SDs) for normally distributed 
variables or medians and interquartile ranges (IQRs) for non-
normally distributed variables. The Mann-Whitney U-test was used 
for comparing non-normally distributed measures and the t-test for 
normally distributed measures. Univariate analysis was conducted 
using Yates-corrected χ2 tests where cell values were <10. Multivariate 
logistic regression analysis was conducted for risk factors for death 
outcome using variables with a p-value of <0.05.
Approval to conduct the study was obtained from the Human 
Research Ethics Committee of the University of Cape Town (ref. 
no. 120/2013).
Results
Between 1 January and 31 December 2011, a total of 1 910 respiratory 
samples were submitted to the NHLS from RCWMCH for viral PCR 
testing. After excluding children without a diagnosis of pneumonia, 
206 AVP cases were identified for analysis, of which 65 (31.6%) were 
co-infected with other respiratory viruses.
Demographic and clinical characteristics (Table 1)
The median age was 12 months (IQR 6 - 24), with a slight male 
predominance. Of the study population, 34.0% (70/206) were 
malnourished and 71.8% (148/206) had community-acquired 
infec tions. Of the clinical features recorded, fever was the most 
common (76.4%). There was a high prevalence of underlying medical 
conditions, with 47.0% of participants having at least one underlying 
medical condition. All HIV-infected children (n=14) were previously 
undiagnosed; antiretroviral therapy was initiated in 12/14 (85.7%) 
during the same admission.
The mean WCC on admission was 15 × 109/L (SD 8.0) and the 
mean haemoglobin concentration 11 g/dL (SD 2.0). The mean CRP 
and PCT were 20 mg/L (IQR 5 - 53, n=145) and 2.5 µg/L (IQR 1 - 12, 
n=10), respectively.
Pneumonia severity
Hypoxia was common, and present in 146/206 patients (70.9%); 76/ 
206 (36.9%) needed ICU admission for respiratory support, of whom 
Table 1. Demographic, clinical and co-infection data in 
children with AVP, 1 January - 31 December 2011 (n=206)
Demographic data
Age at onset (mo.), median (IQR) 12.0 (6 - 24)
Male, n (%) 116 (56.3)
WAZ, mean (SD) 1.38 (1.91)
WAZ <–2, n (%) 70 (34.0)
Community acquired, n (%) 148 (71.8)
Hospital acquired, n (%) 58 (28.1)
Clinical features, n (%)
Rash 5 (2.4)
Conjunctivitis 34 (16.5)
Fever (>38°C) 159 (76.4)
Diarrhoea 31 (15.0)





Immune suppression 19 (9.2)
Prematurity 36 (17.4)
Other (including tracheostomy) 27 (13.1)
HIV status
HIV-exposed, uninfected, n (%) 42 (20.3)
HIV-infected, n (%) 14 (6.7)
CD4%, median (IQR) (n=14) 18.1 (8 - 20.3)
 HIV viral load (log × 106), median (IQR) 
(n=14)
6.4 (5.1 - 6.6)
Co-infections, n (%)
Any viral co-infection 65 (31.5)
Rhinovirus 29 (14.0)
RSV 29 (14.0)
Influenza virus 8 (3.8)
Parainfluenza virus 6 (2.9)
Human metapneumovirus 5 (2.4)
TB 11 (5.3)
Positive blood culture 11 (5.3)
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54/76 (71.1%) were mechanically ventilated, 
31/76 (40.8%) received continuous positive 
airway pressure ventilation, and 13/76 
(17.1%) needed high-frequency oscillatory 
ventilation. The median stay in the ICU was 
9 days (IQR 4 - 17). The median length of 
hospital stay was 10 days (IQR 3 - 21).
Outcomes
Persistent lung disease
Most children recovered completely (168/ 
206, 81.6%) and were discharged with no 
sequelae. Twenty-nine children (14.1%) 
deve loped PLD. Hypoxia (p=0.016) and 
ICU admission (p=0.002) were significantly 
associated with the development of PLD. 
Viral co-infection (8/29 (27.6%) with PLD 
v. 57/177 (32.2%) without PLD; p=0.6) and 
TB (3/29 (10.3%) with PLD v. 8/177 (4.5%) 
without PLD; p=0.18) were not associated 
with PLD. Compared with children without 
PLD, children with PLD had a longer but 
non-significant median ICU stay (9 days v. 
5 days; p=0.06) and a longer median hospital 
stay (41 days v. 9 days; p<0.001).
In-hospital mortality (Table 2)
Eighteen of the 206 children (8.7%) died. 
Hypoxia (p=0.02), ICU admission (p=0.01), 
underlying cardiac disease (p=0.02) and a 
positive blood culture (p=0.001) were associ-
ated with in-hospital mortality on univariate 
analysis (Table 2). Logistic regression analysis 
revealed that ICU admission (odds ratio (OR) 
8.3, 95% confidence interval (CI)  2.3 - 29.0) 
and positive blood culture (OR  11.2, 95% 
CI  2.3 - 54.1) were independently associated 
with mortality. Underlying cardiac disease 
trended towards significant association with 
mortality (OR 2.88, 95% CI 0.98 - 8.5).
Discussion
This study investigated adenoviral respira-
tory infections in SA children, for which 
there were previously no data. In this 
study, adenovirus was isolated in 10.9% 
of all respiratory tract samples tested, 
highlighting the potential contribution of 
adenovirus to pneumonia aetiology in our 
setting. Furthermore, the study confirms 
previous reports of adenovirus causing 
severe pneumonia and significant morbidity 
in children, as supported by our data docu-
menting 36.9% of patients needing ICU 
admission and 14.1% developing PLD.[14,15]
An underlying medical condition and 
malnutrition was found in almost half and 
one-third of patients, respectively, which 
is consistent with previous studies. [9] Pre-
maturity and congenital cardiac dis eases were 
the most common underlying conditions, 
highlighting the vulnerability of children 
with these conditions to AVP. Underlying 
cardiac disease was not an independent risk 
factor for death in our analysis. However, 
this finding must be interpreted with caution 
owing to small numbers. Adenovirus is 
directly cardiotoxic, and is a common cause 
of myocarditis and dilated cardiomyopathy 
in children.[16] Children with heart disease 
are therefore likely to be at increased risk 
of acquiring severe pneumonia with further 
myocardial impairment secondary to the 
direct effects of adenovirus infection on the 
myocardium.
In contrast to other studies, HIV exposure, 
HIV infection and malnutrition were not 
associated with mortality. The prevalence of 
HIV infection in this study was low (6.8%) 
and reflects effective strategies to prevent 
perinatally acquired HIV infection in SA. 
A positive blood culture was also associated 
with increased mortality in this study. The 
synergistic effect produced by bacterial and 
viral co-infection resulting in more severe 
pneumonia has been described.[17]
The severity of AVP as measured by hypo-
xia and need for ICU admission was asso-
ciated with both development of PLD and 
death. This finding is consistent with previous 
studies looking at outcomes following adeno-
viral infections. A meta-analysis of long-
term sequelae of childhood pneumonia 
from mostly developed countries found that 
adenovirus was associated with the highest 
prevalence of sequelae; more than half of 
AVP cases resulted in long-term sequelae 
of chronic obstructive pulmonary disease.[13] 
Three studies from South America identified 
mechanical ventilation, prolonged oxygen 
requirement and prolonged hospitalisation 
as risk factors for the development of 
bronchiectasis obliterans.[10-12] In a study by 
Murtagh et al.,[10] 36% had chronic sequelae 
and 15% died. In our study, 14.1% developed 
PLD and 8.7% died. The lower incidence of 
PLD and death in our cohort compared with 
the Argentinian study could be explained by 
different study design, different definition of 
PLD or different epidemiology of adenovirus 
serotypes and disease spectrum in our setting.
Study limitations
This study has several limitations. Firstly, the 
retrospective search for eligible patients may 
not have represented all AVP cases, as testing 
for respiratory viruses was not routinely 
performed on all children admitted with 
pneumonia. There may have been a bias 
towards more severe pneumonia cases in 
this study, as clinicians were likely to request 
viral testing when pneumonia was more 
severe. Secondly, the attributable role of 
adenovirus infection in pneumonia was not 
established owing to the lack of controls. 
However, co-infection with other viruses or 
TB was not associated with a worse out come. 
Furthermore, evidence of community-acqu-
ired pneumonia causality and increased 
adenovirus-associated morbidity in a paed-
ia tric intensive care setting in our popu-
lation has been described.[6,15] Lastly, we 
were unable to identify adenovirus serotypes 
in this study, as testing for serotype is not 
routinely offered in our setting. Knowledge 
of serotype patterns may explain some 
observed differences in the spectrum of AVP 
disease severity, as described elsewhere.[9]
Conclusions
Adenovirus is potentially an important and 
under-recognised cause of severe pneumonia 
and PLD in young children in SA. Severe AVP 
Table 2. Clinical factors associated with in-hospital mortality in children with AVP
Died, n (%) Alive, n (%) p-value
Age (mo.), median (IQR) 19 (10 - 36) 12 (6 - 24) 0.06
WAZ <–2 7/15 (46.6) 63/177 (35.5) 0.70
Underlying cardiac disease 8/18 (44.4) 40/188 (21.2) 0.02
Any viral co-infection 8/18 (44.4) 57/188 (30.3) 0.21
RSV co-infection 4/18 (22.2) 25/188 (13.2) 0.29
TB co-infection 0 (0) 11/177 (6.2) 0.60
Underlying respiratory disease 1/18 (5.5) 25/188 (13.2) 0.35
Immune suppression 2/18 (11.1) 17/188 (9.0) 0.70
Prematurity 3/18 (16.6) 33/188 (17.5) 0.92
HIV-exposed, uninfected 2/18 (11.1) 40/188 (21.2) 0.53
HIV-infected 0 (0) 14/188 (7.4) 0.61 
Hypoxia 17/18 (94.4) 129/188 (68.6) 0.02
ICU admission 14/18 (77.7) 62/188 (32.9) 0.01
Positive blood culture 4/18 (22.2) 7/188 (3.7) 0.01
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necessitating ICU admission and a positive blood culture are associ-
ated with poor outcome. Early recognition of severe AVP is important 
to identify children at risk of developing chronic sequelae of AVP.
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